ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study
| Autor: | Marleen H. Verlinden, Scott A. West, Lenard A. Adler, Patricia Wozniak, Timothy E. Wilens |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Agonist medicine.medical_specialty Pyrrolidines Side effect Pyridines medicine.drug_class Pilot Projects Neuropsychological Tests Placebo Partial agonist Cognition Double-Blind Method Rating scale Internal medicine medicine Clinical endpoint Humans Attention deficit hyperactivity disorder Attention Nicotinic Agonists Psychiatry Biological Psychiatry Psychiatric Status Rating Scales Cross-Over Studies Dose-Response Relationship Drug medicine.disease Crossover study Memory Short-Term Treatment Outcome Attention Deficit Disorder with Hyperactivity Female Psychology |
| Zdroj: | Biological Psychiatry. 59:1065-1070 |
| ISSN: | 0006-3223 |
| Popis: | Background This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for adult attention-deficit/hyperactivity disorder (ADHD). Methods Adults with ADHD received placebo, 2 mg, 4 mg, or 20 mg of ABT-089 for 2 weeks each in a randomized, double-blind, placebo-controlled, 4 × 4 Latin square design for a total of 8 weeks. In addition to the primary outcome, the Conner’s Adult ADHD Rating Scale (CAARS), secondary rating scales, and neuropsychological and safety assessments were completed. Results A total of 11 adults with well-characterized ADHD completed this crossover study. ABT-089 b.i.d. was superior to placebo for the CAARS Total Symptom Score, which was the primary endpoint (placebo: 38.0 ± 1.9; 2 mg b.i.d.: 32.2 ± 1.9, one-tail p = .021; 4 mg b.i.d.: 33.2 ± 1.9, p = .047; 20 mg b.i.d.: 33.5 ± 1.9, p = .056). ABT-089 was also superior to placebo for the CAARS ADHD Index and Hyperactive/Impulsive scores and the Clinical Global Impression–ADHD Severity score. On the clinical efficacy endpoints, CAARS Total Symptom Score and CAARS Hyperactive/Impulsive score, a shallow inverted U-shaped dose–response curve was observed; however, the dose–response curve for attention and memory effects as measured by computerized cognitive testing seemed dose-linear. No clinically meaningful findings in safety assessments or side effect profile were observed. Conclusions Data from this pilot study suggest that ABT-089 might be effective in treating adult ADHD and that it is well tolerated. On the basis of these promising results, larger, parallel-group ABT-089 studies of longer duration are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect